Circle Pharma is a biopharmaceutical company that focuses on developing macrocycle therapeutics for intracellular protein-protein interactions.

Circle Pharma

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

Google Maps

Content Delivery Network

WordPress

President & CEO

David Earp

Senior Director/Director of Business Operations and Administration

Amy Cowgill

Associate Director, Chemistry

Andrew Bockus

Director, Pharmacology

Bernard Levin

Associate Director

Catie Gleason

Marketing and Product

Eric Connor

Director, Financial Planning & Analysis

Harry Loucks

Engineering

Jie Zheng

Sr. Director and Head, DMPK

Ramesh Bambal

Sr. Director, Medicinal Chemistry

Sammy Metobo

Thilo Schroeder

Peter Svennilson

David C. Spellmeyer

John A. Josey

Walter H. Moos

Paul Park

Chief Business Officer

Scott Lokey

Founder & Chairman

Michael Cox

Senior Vice President, Head of Early Development

DAVID J. EARP

President and CEO, Board of Directors

Evelyn Wang

Vice President

Matthew Jacobson

Co-Founder and Interim CSO

Edward Garmey

Interim Chief Medical Officer

Western US Companies With More Than $1M in Revenue (Top 10K)

Health Care Late Stage Companies With Fewer Than 50 Employees

Therapeutics Companies With More Than $1M in Revenue (Top 10K)

Eli Lilly Portfolio Companies

Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.

The Column Group

Series D - Circle Pharma

Nextech Invest

Series C - Circle Pharma

Series B - Circle Pharma

Series A - Circle Pharma

Mission Bay Capital

Seed Round - Circle Pharma

San Francisco

California

United States

North America

The Week’s 10 Biggest Funding Rounds: Safe Superintelligence Leads With Massive $1B Raise

Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies

Circle Pharma Raises $90M Series D Round

Alliance of Chief Executives on LinkedIn: Circle Pharma raises $54M as part of Series D while macrocycles heat up

Circle Pharma raises $54M as part of Series D while macrocycles heat up

Circle Pharma files IND application for first-in-class cyclin A/B RxL inhibitor for solid tumors

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development

Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B

A platform combining computational structure-based design and synthetic chemistry to develop cell-permeable macrocycle therapeutics targeting intracellular protein-protein interactions.

Macrocyclic therapeutics targeting cyclin proteins A and B, aimed at treating cancers with mutations in the Retinoblastoma pathway and other tumor types.

Development of macrocyclic peptides to address 'undruggable' targets, with a focus on precision oncology.

Philippines

Asia

South Korea

Pakistan

Croatia

Europe

HTML5

Vimeo

Wistia

Google Maps API

Starfield SSL

Office 365

Google Fonts

jQuery

Wordpress

GoDaddy Premium DNS

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 3, 2024 1:12 PM	91fe949a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 3, 2024 3:47 PM	c9d575e3
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	7e46b2e1
crunchbase profile	general	Nov 25, 2024 11:32 AM	77d4498f
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:24 PM	57c0fa8c
peers	general	Sep 3, 2024 1:12 PM	aec9d7db
news basic	general	Sep 3, 2024 1:12 PM	e69d6deb
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CIRC

COM:CIRCLEPHARMA

Circle Pharma